McDermott and Bull executive Search

Other News

Foldax, Inc. Gains Approval to Begin US Clinical Trials of the First and Only Biopolymer Heart Valve Platform

SALT LAKE CITY–(BUSINESS WIRE)–Foldax, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted IDE approval to begin an Early Feasibility Study of the Tria surgical aortic heart valve for the treatment of aortic valve disease. Using breakthrough LifePolymer™ – a proprietary advanced biopolymer material – and […]

Caladrius Biosciences Reports Top-Line Data for the Phase 2a Sanford Project: T-Rex Trial of CLBS03 for Recent Onset Type 1 Diabetes

BASKING RIDGE, N.J., Feb. 13, 2019 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a late-stage therapeutics development biopharmaceutical company with multiple development programs targeting select cardiovascular indications and autoimmune disease, today announced  top-line results from The Sanford Project: T-Rex Study, a prospective, randomized, placebo-controlled, double-blind Phase […]

Semler to Report Fourth Quarter and Year End 2018 Financial Results and Host Conference Call on February 27, 2019

SAN JOSE, Calif., Feb. 14, 2019 /PRNewswire/ — Semler Scientific, Inc. (OTCQB: SMLR), an emerging growth company that provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers, today announced that it will report financial results for fourth quarter and full year ended December 31, 2018 before the open of U.S. […]

Medicure Provides Update on Release of Holdback Funds from Apicore Sale

WINNIPEG, Feb. 13, 2019 /PRNewswire/ – Medicure Inc. (“Medicure” or the “Company“) (TSXV:MPH,OTC: MCUJF), a cardiovascular pharmaceutical company, today announced that it has received notice from the purchaser of Medicure’s interests in Apicore of potential claims against funds held back in respect of representations and warranties under the Apicore sale agreement. The notice does […]

Boehringer Ingelheim and Lilly announce the CAROLINA® cardiovascular outcome trial of Tradjenta® met its primary endpoint of non-inferiority compared with glimepiride

RIDGEFIELD, Conn. and INDIANAPOLIS, Feb. 14, 2019 /PRNewswire/ — Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) announced CAROLINA® (CARdiovascular Outcome study of LINAgliptin versus glimepiride in patients with type 2 diabetes) met its primary endpoint, defined as non-inferiority for Tradjenta® (linagliptin) versus glimepiride in time to first occurrence of cardiovascular death, non-fatal myocardial infarction or […]

iRhythm Technologies Announces Fourth Quarter and Full Year 2018 Financial Results and Provides Full Year 2019 Financial Outlook

SAN FRANCISCO, Feb. 12, 2019 (GLOBE NEWSWIRE) — iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today reported financial results for the three months and full year ended December 31, 2018. Fourth Quarter and Full Year 2018 Highlights Revenue of […]

IBM Watson Health and the Broad Institute Launch Initiative to Help Clinicians Predict the Risk of Cardiovascular Disease with Genomics and AI

CAMBRIDGE, Mass., Feb. 13, 2019 /PRNewswire/ — IBM Watson Health (NYSE: IBM) and the Broad Institute of MIT and Harvard are expanding their partnership to help clinicians better predict the possibility of serious cardiovascular diseases. By working with genomics, clinical data and AI, IBM and the Broad Institute hope this three-year project will help provide doctors with tools to […]

Texas Cardiac Arrhythmia Institute of St. David’s Medical Center is the first in the United States to treat patient under study for evaluation of the ablation catheter-balloon for the treatment of atrial fibrillation

AUSTIN, Texas , February 13, 2019 / PRNewswire / – The Texas Cardiac Arrhythmia Institute (TCAI) of St. David’s Medical Center recently conducted the first procedure in the United States using the new multi-electrode radiofrequency (RF) ablation balloon catheter, HELIOSTAR as part of the STELLAR study. The aim of the study is […]